Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual ...

While inconsistent dosing could have played a role, it still may be possible to identify the patients most likely to see ...

The identification and management of comorbidities are central to the care of patients with atrial fibrillation (AF). The ...

Inflammatory arthritis encompasses a group of autoimmune diseases, including rheumatoid arthritis (RA), psoriatic arthritis ...

There are over six million Americans with heart failure who are at greater risk of losing their cognitive abilities earlier in life, a study suggests.

Older adults with HF with preserved ejection fraction and low vs. high life-space mobility had double the risk for all-cause ...

The DapaTAVI trial assessed the benefits of dapagliflozin in patients discharged after TAVI with a history of heart failure plus 1 of the following comorbidities: LVEF ≤40%, diabetes, or renal ...

In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and heart failure with preserved ejection fraction because they commonly have ...

Human Heat Tolerance Lower Than Previously Believed: Study FindsA study from the University of Ottawa’s Human and ...

Cardiac illnesses are among the trickier ones to manage in the limited time provided for many primary care visits, with ...